AMLX
Amylyx Pharmaceuticals, Inc.
+1.42 (+4.35%)34.05USD419K成交股數3.8B市值–本益比(近四季)–股價營收比–營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | – | – | 0.00-100% | 0.00-100% | 0.00-100% | 0.00-100% | 416K-100% | −1.0M-101% | 88.6M | 108M | 103M | 98.2M |
| 營業成本 | – | – | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8K | 5.9M | 9.4M | 5.2M | 5.6M |
| 毛利 | – | – | 0.00-100% | 0.00-100% | 0.00-100% | 0.00-100% | 416K-100% | −1.0M-101% | 82.7M | 99.1M | 97.5M | 92.6M |
| 毛利率 | – | – | – | – | – | – | 100.0% | 100.8% | 93.3% | 91.4% | 94.9% | 94.3% |
| 研發費用 | 23.8M | 27.6M | 21.2M | 19.9M | 27.2M | 22.1M | 21.2M | 23.3M | 36.6M | 44.9M | 30.0M | 29.0M |
| 銷售管理費用 | 21.9M | 16.2M | 15.4M | 16.2M | 15.6M | 15.7M | 17.8M | 21.6M | 57.8M | 52.2M | 48.7M | 43.4M |
| 營業利益 | −45.7M+7% | −43.8M+16% | −36.6M-52% | −36.0M-53% | −42.9M-65% | −37.8M-2055% | −75.7M-504% | −76.3M-478% | −122M | 1.9M | 18.7M | 20.2M |
| 營業利益率 | – | – | – | – | – | – | -18,187.7% | 7,457.1% | -137.8% | 1.8% | 18.2% | 20.6% |
| 稅後淨利 | −43.4M+5% | −41.3M+15% | −33.0M-55% | −34.4M-53% | −41.4M-65% | −35.9M-859% | −72.7M-448% | −72.7M-429% | −119M | 4.7M | 20.9M | 22.1M |
| 淨利率 | – | – | – | – | – | – | -17,476.9% | 7,106.5% | -134.0% | 4.4% | 20.3% | 22.5% |
| 稀釋 EPS | -0.39-15% | -0.37-12% | -0.28-74% | -0.37-65% | -0.46-74% | -0.42-700% | -1.07-457% | -1.07-445% | -1.75 | 0.07 | 0.30 | 0.31 |
| 稀釋股數 | 111M | 111M | 94.6M | 93.3M | 89.1M | 85.7M | 68.1M | 68.0M | 67.9M | 70.0M | 69.7M | 70.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 49.3M | 229M | 227M | 225M | 58.1M | 59.8M | 71.8M | 75.0M | 171M | 170M | 135M | 248M |
| 應收帳款 | – | – | 88K | 132K | 103K | 300K | 1.7M | 4.1M | 20.4M | 40.1M | 29.4M | 33.5M |
| 存貨 | – | – | – | – | – | – | – | – | – | 38.3M | 32.4M | 24.9M |
| 總資產 | 265M | 294M | 333M | 363M | 195M | 220M | 251M | 332M | 417M | 517M | 467M | 454M |
| 有息負債 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總負債 | 25.4M | 20.4M | 27.4M | 30.7M | 26.7M | 18.3M | 54.5M | 70.9M | 93.0M | 84.0M | 48.2M | 67.2M |
| 股東權益 | 239M | 273M | 305M | 332M | 168M | 201M | 196M | 261M | 324M | 433M | 418M | 386M |
| 負債比 | 9.6% | 7.0% | 8.2% | 8.5% | 13.7% | 8.3% | 21.7% | 21.3% | 22.3% | 16.2% | 10.3% | 14.8% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | – | – | – |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −36.9M-7% | – | – | – | −39.8M | – | – | −489K | – | – | – |
| 資本支出 | – | – | – | – | – | 11K | – | – | 67K | – | – | – |
| 自由現金流 | – | – | – | – | – | −39.8M | – | – | −556K | – | – | – |
| 折舊攤銷 | – | – | – | – | – | – | – | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | -0.6% | – | – | – |
營收拆解
這家公司的 XBRL 沒有標分部、產品或地區營收。多半是單一業務,或只在 10-K 文字裡揭露。
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 0.00 | -100.0% | −145M | –% | -1.53 | −123M |
| FY2024 | 87.4M | -77.1% | −302M | -345.4% | -4.43 | −168M |
| FY2023 | 381M | +1612.9% | 49.3M | 12.9% | 0.70 | 10.7M |
| FY2022 | 22.2M | +7700.0% | −198M | -892.4% | -3.39 | −182M |
| FY2021 | 285K | – | −87.9M | -30,853.0% | -13.35 | −75.2M |